<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2904257311
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRISTIQ 50MG EXTENDED RELEASE TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DESVENLAFAXINE SUCCINATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        78.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PRISTIQ is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder (MDD). PRISTIQ belongs to a class of medicines known as serotonin and norepinephrine reuptake inhibitors (SNRIs).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Pristiq if you : </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to desvenlafaxine, venlafaxine or any of the ingredients in PRISTIQ. See the end of this Medication Guide for a complete list of ingredients in PRISTIQ (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; take a monoamine oxidase inhibitor (MAOI).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have stopped taking a MAOI in the last 14 days. Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Are being treated with the antibiotic linezolid or the intravenous methylene blue.</p><p><strong>Do not start taking an MAOI for at least 7 days after you stop treatment with PRISTIQ.</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Pristiq</p><p>&nbsp;</p><p>What is the most important information I should know about PRISTIQ ?</p><p>PRISTIQ can cause serious side effects, including :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased risk of suicidal thoughts or actions in some children, and young adults within the first few months of treatment. PRISTIQ is not for use in children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions.</p><p>&nbsp;</p><p>How can I watch for and try to prevent suicidal thoughts and actions?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.</p><p>&nbsp;</p><p>Call a healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>&bull; thoughts about suicide or dying</p></td><td style="vertical-align:bottom"><p>&bull; trouble sleeping (insomnia)</p></td></tr><tr><td style="vertical-align:bottom"><p>&bull; attempts to commit suicide</p></td><td style="vertical-align:bottom"><p>&bull; new or worse irritability</p></td></tr><tr><td style="vertical-align:bottom"><p>&bull; new or worse depression</p></td><td style="vertical-align:bottom"><p>&bull; acting aggressive, being angry, or violent</p></td></tr><tr><td style="vertical-align:bottom"><p>&bull; new or worse anxiety</p></td><td style="vertical-align:bottom"><p>&bull; acting on dangerous impulses</p></td></tr><tr><td style="vertical-align:bottom"><p>&bull; feeling very agitated or restless</p></td><td style="vertical-align:bottom"><p>&bull; an extreme increase in activity and talking (mania)</p></td></tr><tr><td style="vertical-align:bottom"><p>&bull; panic attacks</p></td><td style="vertical-align:bottom"><p>&bull; other unusual changes in behavior or mood</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Before taking PRISTIQ tell your healthcare provider about all your medical conditions, including if you: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have cerebrovascular problems or has stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have or had bleeding problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have or have a family history of, bipolar disorder, mania or hypomania.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Have a high cholesterol or high triglycerides.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have or had depression, suicidal thoughts or behavior</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems or liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have or had seizures or convulsions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have low sodium levels in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. Talk to your healthcare provider about the risk to your unborn baby if you take PRISTIQ during pregnancy.</p><p>o&nbsp;&nbsp; Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with PRISTIQ.</p><p>o&nbsp;&nbsp; If you become pregnant during treatment with PRISTIQ, talk to your healthcare provider .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. PRISTIQ can pass into your breast milk. Talk with your healthcare provider about the best way to feed your baby if you take PRISTIQ.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and PRISTIQ</strong></p><p><strong>&nbsp;</strong></p><p>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p>PRISTIQ and other medicines may affect each other causing possible serious side effects. PRISTIQ may affect the way other medicines work and other medicines may affect the way PRISTIQ works. Especially tell your healthcare provider if you take:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; other MAOIs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat migraine headaches known as triptans</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tricyclic antidepressants</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; lithium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tramadol, fentanyl, meperidine, methadone, or other opioids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tryptophan</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; buspirone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; amphetamines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; other medicines containing desvenlafaxine or venlafaxine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; medicines that can affect blood clotting such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat mood, anxiety, psychotic, or thought disorders, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs).</p><p>&nbsp;</p><p>Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take PRISTIQ with your other medicines.</p><p>Do not start or stop any other medicines during treatment with PRISTIQ without talking to your healthcare provider first. Stopping PRISTIQ suddenly may cause you to have serious side effects. See, &ldquo;Possible side effects section&rdquo;</p><p>Know the medicines you take. Keep a list of them to show to your healthcare providers when you get a new medicine.</p><p>&nbsp;</p><p><strong>PRISTIQ with food and, drink and alcohol</strong></p><p>Avoid drinking alcohol while taking PRISTIQ.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>PRISTIQ can pass into your breast milk .Talk with your healthcare provider about the best way to feed your baby if you take PRISTIQ.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Do not drive a car or operate machinery until you know how PRISTIQ affects you</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Take PRISTIQ exactly as your healthcare provider has told you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Take PRISTIQ 1 time a day at about the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; PRISTIQ may be taken either with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swallow PRISTIQ tablets whole, with fluid. Do not divide, crush, cut, chew, or dissolve PRISTIQ tablets .</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; When you take PRISTIQ, you may see something in your stool that looks like a tablet. This is the empty shell from the tablet after the medicine has been absorbed by your body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not take more PRISTIQ than prescribed by your healthcare provider. If you take more PRISTIQ than the amount prescribed, contact your healthcare provider right away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you take too much PRISTIQ, call the Poison Control Center or go to the nearest hospital emergency room right away.</p><p>&nbsp;</p><p>General Information about the safe and effective use of PRISTIQ</p><p>Medicines are sometimes priscribed for purposes other than those listed in a medication guideDo not take PRISTIQ for a condition for which it was not prescribed. Do not give PRISTIQ to other people, even if they have the same symptoms that you have. It may harm them.</p><p>You can ask your pharmacist or healthcare provider for information about PRISTIQ that is written for healthcare professionals.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>Antidepressant medicines may increase suicidal thoughts or actions in some children, and young adults within the first few months of treatment. PRISTIQ is not for use in children.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>PRISTIQ can cause serious side effects, including:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serotonin syndrome. A potentially life-threatening problem called serotonin syndrome can happen when you take PRISTIQ with certain other medicines. See, &ldquo;Do not take PRISTIQ if you:&rdquo; Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the following signs and symptoms of serotonin syndrome:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; agitation</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; seeing or hearing things that are not real (hallucinations)</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; confusion</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; coma</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; changes in blood pressure</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; sweating</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; flushing</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; high body temperature (hyperthermia)</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; tremors, stiff muscles, or muscle twitching</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; loss of coordination</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; seizures</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; nausea, vomiting, diarrhea</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worsened high blood pressure (hypertension). Your healthcare provider should check your blood pressure before and while you are taking PRISTIQ. If you have high blood pressure, it should be controlled before you start treatment with PRISTIQ.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased chance of bleeding or bruising. Taking PRISTIQ with aspirin, NSAIDs, or blood thinners may add to this risk. Tell your healthcare provider right away about any unusual bleeding or bruising, Pristiq may casue heavy&nbsp;bleeding&nbsp;after giving birth.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Eye problems (angle closure glaucoma).</strong> Many antidepressant medicines, including PRISTIQ, may cause a certain type of eye problem called angle-closure glaucoma. Call your healthcare provider if you have changes in your vision or eye pain.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discontinuation syndrome. Suddenly stopping PRISTIQ when you take higher doses may cause you to have serious side effects. Your healthcare provider may want to decrease your dose slowly. Symptoms may include the following,some of which can be severe and last for a long time:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp; dizziness</p><p>o&nbsp; irritability and agitation</p><p>o&nbsp; anxiety</p><p>o&nbsp; aggressiveness (including hostility, rage)</p><p>o&nbsp; tremor</p><p>o&nbsp; sweating</p><p>o&nbsp; seizures</p></td><td style="vertical-align:top"><p>o&nbsp; ringing in your ears (tinnitus)</p><p>o&nbsp; nausea</p><p>o&nbsp; problems sleeping</p><p>o&nbsp; tiredness</p><p>o&nbsp; confusion</p><p>o&nbsp; electric shock sensation (paresthesia)</p></td><td style="vertical-align:top"><p>o&nbsp; headache</p><p>o&nbsp; diarrhea</p><p>o&nbsp; abnormal dreams</p><p>o&nbsp; changes in your mood</p><p>o&nbsp; hypomania</p><p>o&nbsp; problems with eyesight (such as blurred vision and trouble focusing)</p><p>o&nbsp; increase in blood pressure</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures (convulsions).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low sodium levels in your blood (hyponatremia). Low sodium levels can happen during treatment with PRISTIQ. Low sodium levels in your blood may be serious and may cause death. Signs and Symptoms of low sodium levels in your blood may include:</p><p>&middot;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp; difficulty concentrating</p><p>&middot;&nbsp;&nbsp; memory changes</p><p>&middot;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp; weakness and unsteadiness on your feet which can lead to falls</p><p><strong>In severe or more sudden cases, signs and symptoms include: </strong></p><p>&middot;&nbsp;&nbsp; hallucinations (seeing or hearing things that are not real)</p><p>&middot;&nbsp;&nbsp; fainting</p><p>&middot;&nbsp;&nbsp; seizures</p><p>&middot;&nbsp;&nbsp; coma</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lung problems.</strong> Some people who have taken the medicine venlafaxine which is the same kind of medicine as the medicine in PRISTIQ have had lung problems. Symptoms of lung problems include difficulty breathing, cough, or chest discomfort. Tell your healthcare provider right away if you have any of these symptoms.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Sexual </strong><strong>Problems (dysfunction).</strong> Taking serotonin and norepinephrine reuptake inhibitors (SNRIs), including PRISTIQ, may cause sexual problems.</p><p>Symptoms in males may include:</p><p>o &nbsp;Delayed ejaculation or inability to have an ejaculation</p><p>o &nbsp;Decreased sex drive</p><p>o &nbsp;Problems getting or keeping an erection</p><p>Symptoms in females may include:</p><p>o &nbsp;Decreased sex drive</p><p>o &nbsp;Delayed orgasm or inability to have an orgasm</p><p>Talk to your healthcare provider if you develop any changes in your sexual function or if you have any questions or concerns about sexual problems during treatment with PRISTIQ. There may be treatments your healthcare provider can suggest.</p><p><strong>&nbsp;</strong></p><p><strong>The most </strong><strong>common side effects </strong><strong>of </strong><strong>PRISTIQ include: </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems sleeping</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sexual function problems</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>These are not all the possible side effects of PRISTIQ. Tell your healthcare provider about any side effect that bothers you or does not go away.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting side effects: </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><u>To report any side effects :</u></p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><ul><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the bottle &lt;The expiry date refers to the last day of that month.&gt;</p><p>&nbsp;</p><p>Shelf life 36 months.</p><p>&nbsp;</p><p>Do not use this medicine if you notice {description of the visible signs of deterioration}.</p><p>&nbsp;</p><p>Store below 30&deg;C .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is desvenlafaxine (as succinate monohydrate).</p><p>Each tablet contains 50&nbsp;mg of desvenlafaxine (as succinate monohydrate).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: hypromellose, microcrystalline cellulose, talc, magnesium stearate, Opadry II 85F94487 and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The 50 mg prolonged-release tablet is a light pink, square pyramid tablet debossed with “W” (over) “50” on the flat side.
Pristiq 50 mg tablets are available in bottles of 30 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Inc. - United States</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Pfizer Ireland Pharmaceuticals, Newbridge , Ireland</p><p><strong>&nbsp;</strong></p><p><strong>Packed and Released by:</strong></p><p>Pfizer Pharmaceutical LLC, Vega Baja, PR - United States</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بريستيك هو دواء يصرف بوصفة طبية ويستخدم لعلاج البالغين المصابين بنوع معين من الاكتئاب يسمى بالاضطراب الاكتئابي الكبير (MDD). ينتمي بريستيك إلى فئة من الأدوية تُعرف باسم مثبطات استرداد السيروتونين والنورإبينفرين (SNRIs).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال بريستيك</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه ديسفينلافاكسين أو فينلافاكسين أو أي من المكونات الموجودة في بريستيك. انظر الجزء الأخير من دليل استخدام الدواء هذا للاطلاع على قائمة كاملة بمكونات بريستيك (المدرجة في القسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أحد مثبطات أكسيداز أحادي الأمين (MAOI).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد توقفت عن تناول أحد مثبطات أكسيداز أحادي الأمين خلال الـ۱٤ يومًا الأخيرة. اسأل مقدم الرعاية الصحية الخاص بك أو الصيدلي إذا لم تكن متأكدًا من تناولك لأحد مثبطات أكسيداز أحادي الأمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج بالمضاد الحيوي لينيزوليد أو أزرق الميثيلين الذي يستخدم عن طريق الوريد.</p><p dir="RTL"><strong>لا تبدأ في تناول أحد مثبطات أكسيداز أحادي الأمين لمدة ٧ أيام على الأقل بعد أن توقف العلاج ببريستيك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال بريستيك.</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول بريستيك</p><p dir="RTL">&nbsp;</p><p>ما هي المعلومات الأكثر أهمية التي ينبغي أن أعرفها حول بريستيك؟</p><p>يمكن أن يسبب بريستيك آثارًا جانبية خطيرة، بما في ذلك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر التعرض للأفكار أو التصرفات الانتحارية لدى بعض الأطفال والشباب خلال الأشهر القليلة الأولى من العلاج. بريستيك غير مخصص للاستخدام مع الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعد الاكتئاب والأمراض العقلية الخطيرة الأخرى أهم أسباب الأفكار والتصرفات الانتحارية. وقد يكون لدى بعض الأشخاص معدل خطر مرتفع بشكل خاص للتعرض للأفكار أو التصرفات الانتحارية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيف يمكنني الانتباه للأفكار والتصرفات الانتحارية ومحاولة منع حدوثها؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتبه جيدًا لأي تغيرات، خاصة التغيرات المفاجئة، التي تطرأ على الحالة المزاجية، أو السلوكيات، أو الأفكار، أو المشاعر. ويكون ذلك مهم جدًا عند بدء العلاج بدواء مضاد للاكتئاب أو عند تغيير الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بمقدم الرعاية الصحية على الفور للإبلاغ عن التغيرات الجديدة أو المفاجئة في الحالة المزاجية، أو السلوكيات، أو الأفكار، أو المشاعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التزم بحضور جميع زيارات المتابعة مع مقدم الرعاية الصحية في المواعيد المقررة لها. واتصل بمقدم الرعاية الصحية بين الزيارات حسب الحاجة، خاصة إذا كانت لديك مخاوف بشأن الأعراض.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">اتصل بأحد مقدمي الرعاية الصحية على الفور إذا عانيت من أي من الأعراض التالية، خاصة إذا كانت هذه الأعراض حديثة الظهور، أو متفاقمة، أو مثيرة للقلق بالنسبة لك:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">&bull; الأفكار المتعلقة بالانتحار أو الموت</p></td><td style="vertical-align:bottom"><p dir="RTL">&bull; صعوبة النوم (الأرق)</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">&bull; محاولات الانتحار</p></td><td style="vertical-align:bottom"><p dir="RTL">&bull; سرعة الانفعال سواء كان حديث الظهور أو متفاقمًا</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">&bull; الاكتئاب سواء كان حديث الظهور أو متفاقمًا</p></td><td style="vertical-align:bottom"><p dir="RTL">&bull; التصرف بعدوانية، أو بغضب، أو بعنف</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">&bull; القلق سواء كان حديث الظهور أو متفاقمًا</p></td><td style="vertical-align:bottom"><p dir="RTL">&bull; التصرف وفقًا لدوافع خطيرة</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">&bull; الشعور بالتهيج أو التململ الشديد</p></td><td style="vertical-align:bottom"><p dir="RTL">&bull; الزيادة المفرطة في النشاط والكلام (الهوس)</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">&bull; نوبات الهلع</p></td><td style="vertical-align:bottom"><p dir="RTL">&bull; التغيرات الأخرى غير المعتادة في السلوك أو الحالة المزاجية</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قبل تناول بريستيك، أخبر مقدم الرعاية الصحية الخاص بك حول كل ما يخص حالاتك الطبية، بما في ذلك إذا: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ضغط الدم المرتفع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات دماغية وعائية أو كنت قد أصبت بسكتة دماغية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني أو سبق أن عانيت من مشكلات النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالاضطراب ثنائي القطب، أو الهوس، أو الهوس الخفيف أو كان لديك تاريخ عائلي من الإصابة بهذه الأمراض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ارتفاع نسبة الكولستيرول أو ارتفاع نسبة ثلاثيات الجليسريد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني، أو سبق أن عانيت، من الإصابة بالاكتئاب أو بأفكار أو سلوكيات انتحارية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في الكلى أو مشكلات في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني، أو سبق أن عانيت، من الإصابة بنوبات أو تشنجات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من انخفاض مستويات الصوديوم في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملًا أو تخططين للحمل. تحدثي إلى مقدم الرعاية الصحية الخاص بكِ حول الخطر المعرض له جنينكِ إذا تناولتِ بريستيك أثناء الحمل.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري مقدم الرعاية الصحية الخاص بكِ إذا أصبحتِ حاملًا أو إذا كنتِ تعتقدين أنكِ حامل أثناء فترة العلاج ببريستيك.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحتِ حاملًا أثناء فترة العلاج ببريستيك، فتحدثي إلى مقدم الرعاية الصحية الخاص بكِ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ ترضعين رضاعة طبيعية أو تخططين للقيام بالرضاعة الطبيعية. حيث يمكن أن يعبر بريستيك إلى لبن الثدي. تحدثي مع مقدم الرعاية الصحية الخاص بكِ بشأن أفضل الطرق لإرضاع طفلكِ إذا استخدمتِ بريستيك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر مقدم الرعاية الصحية الخاص بك بشأن جميع الأدوية التي تتناولها، بما في ذلك الأدوية والفيتامينات والمكملات العشبية التي يتم الحصول عليها بوصفة طبية أو بدونها.</strong></p><p dir="RTL"><strong>قد يؤثر بريستيك والأدوية الأخرى على بعضها البعض مما يسبب آثارًا جانبية خطيرة محتملة. قد يؤثر بريستيك على كيفية عمل الأدوية الأخرى وقد تؤثر الأدوية الأخرى على كيفية عمل بريستيك.</strong></p><p dir="RTL"><strong>بشكل خاص، أخبر مقدم الرعاية الخاص بك إذا كنت تتناول:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات أكسيداز أحادي الأمين الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج حالات الصداع النصفي تُعرف باسم مركبات التريبتان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب ثلاثية الحلقات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترامادول، أو فينتانيل، أو ميبيريدين، أو ميثادون، أو المواد الأفيونية الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريبتوفان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسبيرون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركبات الأمفيتامين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى تحتوي على ديسفينلافاكسين أو فينلافاكسين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية يمكن أن تؤثر على تخثر الدم مثل الأسبرين، مضادات الالتهاب غير الستيرويدية (NSAIDs)، وارفارين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُستخدم لعلاج الاضطرابات المزاجية، أو الذهانية، أو اضطرابات القلق، أو التفكير، بما في ذلك مثبطات استرداد السيروتونين الانتقائية (SSRIs) ومثبطات استرداد السيروتونين والنورإبينفرين (SNRIs).</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل مقدم الرعاية الصحية الخاص بك إذا كنت غير متأكد مما إذا كنت تتناول أيًا من هذه الأدوية أم لا. يمكن أن يخبرك مقدم الرعاية الصحية الخاص بك ما إذا كان من الآمن تناول بريستيك مع أدويتك الأخرى أم لا.</p><p dir="RTL">لا تبدأ أو توقف استخدام أي أدوية أخرى أثناء فترة العلاج ببريستيك دون التحدث إلى مقدم الرعاية الصحية الخاص بك أولًا. فقد يتسبب إيقاف بريستيك فجأة في إصابتك بآثار جانبية خطيرة. انظر قسم &quot;الأعراض الجانبية&quot;</p><p dir="RTL">كن على دراية بالأدوية التي تتناولها. واحتفظ بقائمة بها حتى تعطيها لمقدمي الرعاية الصحية الخاصين بك عندما يوصف لك دواءً جديدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول بريستيك مع الطعام والشراب</strong></p><p dir="RTL">تجنب شرب الكحوليات أثناء تناول بريستيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حيث يمكن أن يعبر بريستيك إلى لبن الثدي. تحدثي مع مقدم الرعاية الصحية الخاص بكِ بشأن أفضل الطرق لإرضاع طفلكِ إذا استخدمتِ بريستيك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير بريسيتك على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقم بقيادة السيارات أو تشغيل الآلات حتى تعرف مدى تأثير بريستيك عليك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول بريستيك بالطريقة التي أخبرك بها مقدم الرعاية الصحية الخاص بك بالضبط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول بريستيك مرة واحدة في اليوم في الوقت نفسه تقريبًا من كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول بريستيك مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع أقراص بريستيك كاملة مع شرب أحد السوائل. لا تقم بتقسيم أقراص بريستيك، أو طحنها، أو قطعها، أو مضغها، أو إذابتها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تناولك لبريستيك، قد تلاحظ ظهور ما يشبه القرص في البراز. هذا هو الغلاف الخارجي الفارغ للقرص بعد إتمام امتصاص الجسم للدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة من بريستيك أكبر مما وصفه لك مقدم الرعاية الصحية الخاص بك. إذا تناولت كمية من بريستيك أكبر من الكمية الموصوفة لك، فاتصل بمقدم الرعاية الصحية الخاص بك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناولت كمية أكبر من اللازم من بريستيك، فاتصل فورًا بمركز مكافحة السموم أو توجه إلى غرفة الطوارئ بأقرب مستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p>معلومات عامة حول الاستخدام الآمن والفعال لبريستيك</p><p dir="RTL">أحيانًا ما توصف الأدوية لأغراض غير تلك المدرجة في الدليل الدوائي. لا تتناول بريستيك لحالة لم يوصف لها. لا تعط بريستيك لأشخاص آخرين، حتى إذا كانوا يعانون من نفس الأعراض التي تعاني منها. فقد يسبب لهم ضررًا.</p><p dir="RTL">يمكنك أن تطلب من الصيدلي الذي تتعامل معه أو مقدم الرعاية الصحية الخاص بك تزويدك بالمعلومات الموجهة لمتخصصي الرعاية الصحية حول بريستيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تزيد الأدوية المضادة للاكتئاب من الأفكار أو التصرفات الانتحارية لدى بعض الأطفال والشباب خلال الأشهر القليلة الأولى من العلاج. بريستيك غير مخصص للاستخدام مع الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية استفسارات أخرى عن كيفية استخدام هذا الدواء، فاستشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p>يُمكن لبريستيك أن يسبب آثارًا جانبية خطيرة، بما في ذلك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة السيروتونين. يمكن أن تحدث مشكلة مهددة للحياة بشكل محتمل تُسمى متلازمة السيروتونين، وذلك عندما تتناول بريستيك بالتزامن مع بعض الأدوية الأخرى. انظر قسم &quot;موانع استعمال بريستيك إذا كنت:&quot;. اتصل بمقدم الرعاية الصحية الخاص بك أو توجه فورًا إلى غرفة الطوارئ بأقرب مستشفى إذا أصبت بأي من العلامات والأعراض التالية لمتلازمة السيروتونين:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سماع أشياء غير حقيقية (الهلاوس)</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغيبوبة</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في ضغط الدم</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العرق</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة حرارة الجسم (فرط الحرارة)</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعاش، أو تيبس العضلات، أو ارتعاش العضلات</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان التناسق</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، القيء، الإسهال</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع (ارتفاع ضغط الدم) حديث الظهور أو المتفاقم. ينبغي على مقدم الرعاية الصحية الخاص بك التحقق من مستويات ضغط دمك قبل وأثناء تناولك لبريستيك. إذا كنت تعاني من ضغط الدم المرتفع، ينبغي السيطرة على هذا الارتفاع قبل أن تبدأ العلاج ببريستيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة احتمال حدوث النزيف أو التكدم. قد يؤدي تناول بريستيك بالتزامن مع الأسبرين، أو مضادات الالتهاب غير الستيرويدية، أو الأدوية المسيلة للدم إلى زيادة هذا الخطر. أخبر مقدم الرعاية الصحية الخاص بك فورًا بشأن أي نزيف أو تكدم غير معتاد، قد يسبب بريستيك نزيفًا شديدًا بعد الولادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات العين (زرق تضيق الرؤية). قد تسبب العديد من الأدوية المضادة للاكتئاب، بما في ذلك بريستيك، نوعًا معينًا من مشكلات العين يُسمى زرق تضيق الرؤية. اتصل بمقدم الرعاية الصحية الخاص بك إذا تعرضت لتغيرات في بصرك أو أصبت بألم في العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>متلازمة إيقاف العلاج. </strong>إن إيقاف بريستيك فجأة عندما تكون الجرعات التي تتناولها عالية قد يتسبب في إصابتك بآثار جانبية خطيرة. قد يرغب مقدم الرعاية الصحية الخاص بك في تقليل جرعتك ببطء. قد تتضمن الأعراض ما يلي، ويمكن أن يكون بعضها شديدًا ويستمر لمدة طويلة:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; الدوار</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; رنين في أذنيك (طنين الأذن)</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; الصداع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; سرعة الانفعال والتهيج</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; الغثيان</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; الإسهال</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; العدوانية (بما في ذلك التصرف بعدائية، والغضب)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; الرعاش</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; العرق</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; النوبات</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; مشكلات النوم التعب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; الارتباك</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; الإحساس بصدمة كهربية (التنميل)</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; الأحلام غير الطبيعية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; التغيرات المزاجية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; الهوس الخفيف</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; مشكلات في الرؤية (مثل تغيم الرؤية وصعوبة التركيز)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات (التشنجات)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في دمك (نقص صوديوم الدم). يمكن أن تنخفض مستويات الصوديوم أثناء العلاج ببريستيك. قد يكون انخفاض مستويات الصوديوم في دمك خطيرًا وقد يسبب الوفاة. قد تتضمن علامات وأعراض انخفاض مستويات الصوديوم في دمك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التركيز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الذاكرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف وعدم ثبات القدمين على الأرض مما قد يؤدي إلى حوادث السقوط</p><p dir="RTL">في الحالات الشديدة أو المفاجئة بدرجة أكبر فإن العلامات والأعراض تتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهلاوس (رؤية أو سماع أشياء غير حقيقية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغيبوبة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات بالرئة.</strong> أصيب بعض الأشخاص الذين استخدموا دواء فينلافاكسين، وهو نفس نوع الدواء الموجود في بريستيك، بمشكلات في الرئة. تتضمن أعراض مشكلات الرئة صعوبة التنفس، أو السعال، أو ضيق الصدر. أبلغ مقدم الرعاية الصحية الخاص بك على الفور إذا أصبت بأي من هذه الأعراض.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مشكلات جنسية (خلل وظيفي).</strong> تناول مثبطات استرداد السيروتونين والنورإبينفرين، بما في ذلك بريستيك، يمكن أن يسبب مشكلات جنسية.</p><p dir="RTL">يمكن أن تتضمن الأعراض في الذكور:</p><p dir="RTL">o&nbsp; تأخر القذف أو عدم القدرة على القذف</p><p dir="RTL">o&nbsp; انخفاض الرغبة الجنسية</p><p dir="RTL">o&nbsp; مشكلات في الانتصاب أو الاحتفاظ بالانتصاب</p><p dir="RTL">يمكن أن تتضمن الأعراض في الإناث:</p><p dir="RTL">o&nbsp; انخفاض الرغبة الجنسية</p><p dir="RTL">o&nbsp; تأخر الوصول إلى النشوة الجنسية أو عدم القدرة على الوصول إليها</p><p dir="RTL">تحدث إلى مقدم الرعاية الصحية الخاص بك في حالة الإصابة بأي تغييرات في نشاطك الجنسي أو إذا كانت لديك أي أسئلة أو مخاوف بشأن المشكلات الجنسية أثناء العلاج ببريستيك. فقد تكون هناك علاجات يمكن أن يقترحها مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الآثار الجانبية الأكثر شيوعًا لبريستيك:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات النوم</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العرق</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الوظائف الجنسية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">هذه ليست كل الآثار الجانبية المحتملة لبريستيك. أخبر مقدم الرعاية الصحية الخاص بك عن أي أثر جانبي يسبب لك الإزعاج أو لا يزول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الإبلاغ عن الأعراض الجانبية:</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد:<strong> </strong>۱۹۹۹۹</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة &lt; يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.&gt;<br /><br />صلاحية المستحضر ۳٦ شهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت {وصف العلامات الظاهرة التي تدل على فساده}.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتخزينه في درجة حرارة اقل&nbsp; من ۳۰ درجة مئوية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ديسفينلافاكسين (في صورة سكسينات أحادي الهيدرات).</p><p dir="RTL">يحتوي كل قرص على ٥۰ ملجم من ديسفينلافاكسين (في صورة سكسينات أحادي الهيدرات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: هيبروميلوز، وسليلوز بلوري مكروي، وتلك، وستيارات المغنيسيوم، أوبادري &rlm;II&rlm; 85F94487: وماء مقطر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن القرص ممتد الإطلاق ٥۰ ملجم يكون بلون وردي فاتح، هرمي مربع محفور عليه علامة &quot;W&quot; (فوق) &quot;50&quot; على الجانب المسطح.</p><p dir="RTL">تتوفر أقراص بريستيك ٥۰ ملجم في زجاجات تحتوي على ۳۰ قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق </strong></p><p dir="RTL">Pfizer Inc. - United States<strong> </strong></p><p dir="RTL">الولايات المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة:</strong></p><p dir="RTL">Pfizer Ireland Pharmaceuticals, Newbridge, Ireland</p><p dir="RTL">إيرلندا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تمت تعبئته وتوزيعه بواسطة:</strong></p><p dir="RTL">Pfizer Pharmaceutical LLC, Vega Baja, PR - United States<strong>، </strong></p><p dir="RTL">الولايات المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس/آب ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pristiq 50 mg extended-release tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Pristiq 50 mg extended-release tablet contains 76 mg of desvenlafaxine succinate monohydrate equivalent to 50 mg of desvenlafaxine.

For the full list of excipients, see section 6.1.

PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine (O desmethylvenlafaxine) is the major active metabolite of the antidepressant venlafaxine, a medication used to treat major depressive disorder. 

Desvenlafaxine is designated RS-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C16H25NO2 (free base) and C16H25NO2•C4H6O4•H2O (succinate monohydrate). Desvenlafaxine succinate monohydrate has a molecular weight of 399.48. The structural formula is shown below.  
 
Desvenlafaxine succinate is a white to off-white powder that is soluble in water. The solubility of desvenlafaxine succinate is pH dependent. Its octanol:aqueous system (at pH 7.0) partition coefficient is 0.21. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pristiq 50 mg extended-release tablets: light pink, square pyramid tablet debossed with “W” (over) “50” on the flat side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD) [see section 5.1 Pharmacodynamic properties].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General Instructions for Use</p><p>The recommended dose for PRISTIQ is 50&nbsp;mg once daily, with or without food. The 50&nbsp;mg dose is both a starting dose and the therapeutic dose. PRISTIQ should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.</p><p>&nbsp;</p><p>In clinical studies, doses of 10&nbsp;mg to 400&nbsp;mg per day were studied. In clinical studies, doses of 50&nbsp;mg to 400&nbsp;mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50&nbsp;mg per day and adverse reactions and discontinuations were more frequent at higher doses.</p><p>&nbsp;</p><p>The 25&nbsp;mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see section 4.2 Posology and method of administration and 4.4 Special warnings and precautions].</p><p>&nbsp;</p><p>Dosage Recommendations for Patients with Renal Impairment</p><p>The maximum recommended dose in patients with moderate renal impairment (24-hr&nbsp;creatinine clearance [Cl<sub>Cr</sub>]&nbsp;=&nbsp;30 to 50&nbsp;mL/min, Cockcroft-Gault [C-G]) is 50&nbsp;mg per day. The maximum recommended dose in patients with severe renal impairment (Cl<sub>Cr</sub><sub> </sub>15 to 29&nbsp;mL/min, C-G) or end-stage renal disease (ESRD, Cl<sub>Cr</sub> &lt; 15&nbsp;mL/min, C-G) is 25&nbsp;mg every day or 50&nbsp;mg every other day. Supplemental doses should not be given to patients after dialysis. [see section 4.4 Special warnings and precautions and 5.2 Pharmacokinetic properties].</p><p>&nbsp;</p><p>Dosage Recommendations for Patients with Hepatic Impairment</p><p>The recommended dose in patients with moderate to severe hepatic impairment (Child-Pugh score 7 to 15) is 50&nbsp;mg per day. Dose escalation above 100&nbsp;mg per day is not recommended [see section 4.4 Special warnings and precautions and 5.2 Pharmacokinetic properties].</p><p>&nbsp;</p><p>Maintenance/Continuation/Extended Treatment</p><p>It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Longer-term efficacy of PRISTIQ (50-400&nbsp;mg) was established in two maintenance trials [see section 5.1 Pharmacological properties]. Patients should be periodically reassessed to determine the need for continued treatment.</p><p>&nbsp;</p><p>Discontinuing PRISTIQ</p><p>Adverse reactions may occur upon discontinuation of PRISTIQ [see section 4.4 Special warnings and precautions]. Gradually reduce the dosage rather than stopping PRISTIQ abruptly when discontinuing therapy with PRISTIQ. In some patients, discontinuation may need to occur over a period of several months.</p><p>&nbsp;</p><p>Switching Patients From Other Antidepressants to PRISTIQ</p><p>Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to PRISTIQ. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms.</p><p>&nbsp;</p><p>Switching Patients to or from a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</p><p>&nbsp;</p><p>At least 14&nbsp;days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with PRISTIQ. Conversely, at least 7&nbsp;days should be allowed after stopping PRISTIQ before starting an MAOI intended to treat psychiatric disorders [see section 4.3 Contraindications].</p><p>&nbsp;</p><p><strong>Use of PRISTIQ with other MAOIs such as Linezolid or Methylene Blue</strong></p><p>Do not start PRISTIQ in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered [see section 4.3 Contraindications].</p><p>&nbsp;</p><p>In some cases, a patient already receiving PRISTIQ therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, PRISTIQ should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 7&nbsp;days or until 24&nbsp;hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with PRISTIQ may be resumed 24&nbsp;hours after the last dose of linezolid or intravenous methylene blue [see<em> </em>section 4.4 Special warnings and precautions].</p><p>&nbsp;</p><p>The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1&nbsp;mg/kg with PRISTIQ is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use [see section 4.4 Special warnings and precautions].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the PRISTIQ formulation. Angioedema has been reported in patients treated with PRISTIQ [see section 4.8 Undesirable effects].

•	The use of MAOIs intended to treat psychiatric disorders with PRISTIQ or within 7 days of stopping treatment with PRISTIQ is contraindicated because of an increased risk of serotonin syndrome. The use of PRISTIQ within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see section 4.2 Posology and method of administration and 4.4 Special warnings and precautions].

•	Starting PRISTIQ in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see section 4.2 Posology and method of administration and 4.4 Special warnings and precautions for use].

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients</p><p>Patients with MDD, both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age&nbsp;24; there was a reduction with antidepressants compared to placebo in adults aged&nbsp;65 and older.</p><p>&nbsp;</p><p>The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24&nbsp;short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295&nbsp;short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000&nbsp;patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p>Table 1</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Age Range </strong></p></td><td style="vertical-align:bottom"><p><strong>Drug-Placebo Difference in Number of Cases of Suicidality per 1,000 Patients Treated </strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Increases Compared to Placebo</p></td></tr><tr><td style="vertical-align:bottom"><p>&lt;18</p></td><td style="vertical-align:bottom"><p>14 additional cases</p></td></tr><tr><td style="vertical-align:bottom"><p>18 to 24</p></td><td style="vertical-align:bottom"><p>5 additional cases</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Decreases Compared to Placebo</p></td></tr><tr><td style="vertical-align:bottom"><p>25 to 64</p></td><td style="vertical-align:bottom"><p>1 fewer case</p></td></tr><tr><td style="vertical-align:bottom"><p>&ge;65</p></td><td style="vertical-align:bottom"><p>6 fewer cases</p></td></tr></tbody></table><p>&nbsp;</p><p>No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide.</p><p>&nbsp;</p><p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression.</p><p>&nbsp;</p><p>All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</p><p><strong>&nbsp;</strong></p><p>The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p><p>&nbsp;</p><p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient&rsquo;s presenting symptoms.</p><p>&nbsp;</p><p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see section 4.2 Posology and method of administration].</p><p>&nbsp;</p><p>Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers<strong>. </strong></p><p><strong>&nbsp;</strong></p><p>Prescriptions for PRISTIQ should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.</p><p>&nbsp;</p><p><u>Screening patients for bipolar disorder</u></p><p>A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that PRISTIQ is not approved for use in treating bipolar depression.</p><p>&nbsp;</p><p>Serotonin Syndrome</p><p>Serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective-serotonin reuptake inhibitors (SSRIs), including PRISTIQ, can precipitate serotonin syndrome, a potentially life‑threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. John&rsquo;s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see section 4.3 Contraindications and &nbsp;section 4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other medicinal products and other forms of interaction]. Serotonin syndrome can also occur when these drugs are used alone.</p><p>&nbsp;</p><p>Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).</p><p>&nbsp;</p><p>The concomitant use of PRISTIQ with MAOIs is contraindicated. In addition, do not initiate PRISTIQ in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking PRISTIQ, discontinue PRISTIQ before initiating treatment with the MAOI [see section 4.3 Contraindications and 4.5 Interaction with other medicinal products and other forms of interaction].</p><p>&nbsp;</p><p>Monitor all patients taking PRISTIQ for the emergence of serotonin syndrome. Discontinue treatment with PRISTIQ and any concomitant serotonergic agents immediately if the above symptoms occur and initiate supportive symptomatic treatment. If concomitant use of PRISTIQ with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.</p><p>&nbsp;</p><p>Elevated Blood Pressure</p><p>Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies [see section 4.8 Undesirable side effects]. Pre-existing hypertension should be controlled before initiating treatment with PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with PRISTIQ.</p><p>Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving PRISTIQ, either dose reduction or discontinuation should be considered [see section<strong> </strong>4.8 Undesirable side effects].</p><p>&nbsp;</p><p>Increased Risk of Bleeding</p><p>Drugs that interfere with serotonin reuptake inhibition, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see section 4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation]. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life‑threatening hemorrhages.</p><p>&nbsp;</p><p>Inform patients about the increased risk of bleeding associated with the concomitant use of PRISTIQ and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing PRISTIQ.</p><p>&nbsp;</p><p>SSRIs/SNRIs may increase the risk of postpartum hemorrhage.</p><p>&nbsp;</p><p>Angle Closure Glaucoma</p><p>The pupillary dilation that occurs following use of many antidepressant drugs including PRISTIQ may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including PRISTIQ, in patients with untreated anatomically narrow angles.</p><p>&nbsp;</p><p>Activation of Mania/Hypomania</p><p>During all MDD phase 2 and phase 3 studies, mania was reported for approximately 0.02% of patients treated with PRISTIQ. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania.</p><p>&nbsp;</p><p>Discontinuation Syndrome</p><p>Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. [see section &nbsp;4.8 Undesirable side effects].</p><p>&nbsp;</p><p>There have been postmarketing reports of serious discontinuation symptoms with PRISTIQ, which can be protracted and severe. Completed suicide, suicidal thoughts, and severe aggression (including hostility, rage, and homicidal ideation) have been observed in patients during reduction in PRISTIQ dosage, including during discontinuation. Other postmarketing reports describe visual changes (such as blurred vision or trouble focusing) and increased blood pressure after stopping or reducing the dose of PRISTIQ<em>.</em></p><p>&nbsp;</p><p>Patients should be monitored when discontinuing treatment with PRISTIQ. A gradual reduction in the dose, rather than abrupt cessation, is recommended. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered<em>. </em>Subsequently, the healthcare provider may continue decreasing the dose, but at a more gradual rate. In some patients, discontinuation may need to occur over a period of several months [see section 4.2 Posology and method of administration].</p><p>&nbsp;</p><p>Seizure</p><p>Cases of seizure have been reported in pre-marketing clinical studies with PRISTIQ. PRISTIQ has not been systematically evaluated in patients with a seizure disorder. Patients with a history of seizures were excluded from pre-marketing clinical studies. PRISTIQ should be prescribed with caution in patients with a seizure disorder.</p><p>&nbsp;</p><p>Hyponatremia</p><p>Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110&nbsp;mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see section 5.3 Pharmacokinetic properties]<em>. </em>Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.</p><p>&nbsp;</p><p>Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.</p><p>&nbsp;</p><p>Interstitial Lung Disease and Eosinophilic Pneumonia</p><p>Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with PRISTIQ who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of PRISTIQ should be considered.</p><p>&nbsp;</p><p><strong>Sexual Dysfunction</strong></p><p>Use of SNRIs, including PRISTIQ, may cause symptoms of sexual dysfunction [see section 4.8 Undesirable side effects]. In male patients, SNRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SNRI use may result in decreased libido and delayed or absent orgasm.</p><p>&nbsp;</p><p>It is important for prescribers to inquire about sexual function prior to initiation of PRISTIQ and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.</p><p>&nbsp;</p><p>Pediatric Use</p><p>The safety and effectiveness of PRISTIQ have not been established in pediatric patients for the treatment of MDD.</p><p>&nbsp;</p><p>Efficacy was not demonstrated in two adequate and well controlled, 8-week, randomized, double-blind, placebo-controlled, parallel group studies conducted in 587 patients (7 to 17&nbsp;years of age) for the treatment of MDD.</p><p>&nbsp;</p><p>Antidepressants, such as PRISTIQ, increase the risk of suicidal thoughts and behaviors in pediatric patients [see the Boxed Warning and section 4.4 Special warnings and precautions for use].</p><p>PRISTIQ was associated with a decrease in body weight in placebo-controlled trials in pediatric patients with MDD. The incidence of weight loss (&ge;3.5% of baseline weight) was 22%, 14%, and 7% for patients treated with low dose PRISTIQ, high dose PRISTIQ, and placebo, respectively.</p><p>&nbsp;</p><p>The risks associated with longer term PRISTIQ use were assessed in 6-month, open-label extension studies in pediatric patients (7 to 17 years of age) with MDD. Pediatric patients (7 to 17&nbsp;years of age) had mean changes in weight that approximated expected changes, based on data from age- and sex-matched peers.</p><p>&nbsp;</p><p>In clinical trials, when compared to adult patients receiving the same dose of PRISTIQ, exposure to desvenlafaxine was similar in adolescent patients 12 to 17 years of age, and was about 30% higher in pediatric patients 7 to 11 years of age.</p><p>&nbsp;</p><p><u>Juvenile Animal Studies </u></p><p>In a juvenile animal study, male and female rats were treated with desvenlafaxine (75, 225 and 675&nbsp;mg/kg/day) starting on postnatal day (PND) 22 through 112. Behavioral deficits (longer time immobile in a motor activity test, longer time swimming in a straight channel test, and lack of habituation in an acoustic startle test) were observed in males and females but were reversed after a recovery period. A No Adverse Effect Level (NOAEL) was not identified for these deficits. The Low Adverse Effect Level (LOAEL) was 75 mg/kg/day which was associated with plasma exposure (AUC) twice the levels measured with a pediatric dose of 100&nbsp;mg/day.</p><p>&nbsp;</p><p>In a second juvenile animal study, male and female rats were administered desvenlafaxine (75, 225 or 675 mg/kg/day) for 8-9 weeks starting on PND 22 and were mated with na&iuml;ve counterparts. Delays in sexual maturation and decreased fertility, number of implantation sites and total live embryos were observed in treated females at all doses. The LOAEL for these findings is 75 mg/kg/day which was associated with an AUC twice the levels measured with a pediatric dose of 100 mg/day. These findings were reversed at the end of a 4-week recovery period. The relevance of these findings to humans is not known.</p><p>&nbsp;</p><p>Geriatric Use</p><p>Of the 4,158<strong> </strong>patients in pre-marketing clinical studies with PRISTIQ, 6% were 65&nbsp;years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients; however, in the short-term placebo-controlled studies, there was a higher incidence of systolic orthostatic hypotension in patients &ge;65 years of age compared to patients &lt;65 years of age treated with PRISTIQ [see section 4.8 Undesirable effects]. For elderly patients, possible reduced renal clearance of PRISTIQ should be considered when determining dose [see section 4.2 Posology and method of administration and 5.3 Pharmacokinetic properties].</p><p>&nbsp;</p><p>SSRIs and SNRIs, including PRISTIQ, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see&nbsp;section 4.4 Special warnings and precautions for use].</p><p>&nbsp;</p><p>Renal Impairment</p><p>Adjust the maximum recommended dosage in patients with moderate or severe renal impairment (CLcr 15 to 50&nbsp;mL/min, C-G), or end-stage renal disease (CLcr &lt; 15 mL/min, C‑G) [see section 4.2 Posology and method of administration <em>and 5.3 Pharmacokinetic properties]</em><em>.</em><em> </em></p><p>&nbsp;</p><p>Hepatic Impairment</p><p>Adjust the maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh score 7 to 15) [see section 4.2 Posology and method of administration <em>and 5.3 Pharmacokinetic properties</em>].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drugs Having Clinically Important Interactions with PRISTIQ</p><p>&nbsp;</p><p><strong>Table 2: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinically Important Drug Interactions with PRISTIQ</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Monoamine Oxidase Inhibitors (MAOI)</p></td></tr><tr><td style="vertical-align:top"><p><em>Clinical Impact</em></p></td><td style="vertical-align:top"><p>The concomitant use of SSRIs and SNRIs including PRISTIQ with MAOIs increases the risk of serotonin syndrome.</p></td></tr><tr><td style="vertical-align:top"><p><em>Intervention</em></p></td><td style="vertical-align:top"><p>Concomitant use of PRISTIQ is contraindicated:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With an MAOI intended to treat psychiatric disorders or within 7&nbsp;days of stopping treatment with PRISTIQ.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Within 14&nbsp;days of stopping an MAOI intended to treat psychiatric disorders.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In a patient who is being treated with linezolid or intravenous methylene blue.<em> </em></p><p>[see section 4.2 Posology and method of administration, 4.3 Contraindications and 4.4 Special Warnings and Precautions for use]<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Examples</em></p></td><td style="vertical-align:top"><p>selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Other Serotonergic Drugs</p></td></tr><tr><td style="vertical-align:top"><p><em>Clinical Impact</em></p></td><td style="vertical-align:top"><p>Concomitant use of PRISTIQ with other serotonergic drugs increases the risk of serotonin syndrome.</p></td></tr><tr><td style="vertical-align:top"><p><em>Intervention</em></p></td><td style="vertical-align:top"><p>Monitor for symptoms of serotonin syndrome when PRISTIQ is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of PRISTIQ and/or concomitant serotonergic drugs<em> </em>[see section 4.4 Special Warnings and Precautions for use].<strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Examples</em></p></td><td style="vertical-align:top"><p>other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John&#39;s Wort</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Drugs that Interfere with Hemostasis</p></td></tr><tr><td style="vertical-align:top"><p><em>Clinical Impact</em></p></td><td style="vertical-align:top"><p>Concomitant use of PRISTIQ with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding. This may be due to the effect of PRISTIQ on the release of serotonin by platelets.</p></td></tr><tr><td style="vertical-align:top"><p><em>Intervention</em></p></td><td style="vertical-align:top"><p>Closely monitor for bleeding for patients receiving an antiplatelet or anticoagulant drug when PRISTIQ is initiated or discontinued [see section 4.4 Special Warnings and Precautions for use].<strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Examples</em></p></td><td style="vertical-align:top"><p>NSAIDs, aspirin, and warfarin</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Drugs that are Primarily Metabolized by CYP2D6</p></td></tr><tr><td style="vertical-align:top"><p><em>Clinical Impact</em></p></td><td style="vertical-align:top"><p>Concomitant use of PRISTIQ increases C<sub>max</sub> and AUC of a drug primarily metabolized by CYP2D6<em> </em>which may increase the risk of toxicity of the CYP2D6 substrate drug [see section 5.3 Pharmacokinetic properties].</p></td></tr><tr><td style="vertical-align:top"><p><em>Intervention</em></p></td><td style="vertical-align:top"><p>Original dose should be taken when co-administered with PRISTIQ 100&nbsp;mg or lower. Reduce the dose of these drugs by up to one-half if co-administered with 400&nbsp;mg of PRISTIQ.</p></td></tr><tr><td style="vertical-align:top"><p><em>Examples</em></p></td><td style="vertical-align:top"><p>desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Drugs Having</strong><strong> No Clinically Important Interactions with PRISTIQ</strong></p><p>Based on pharmacokinetic studies, no dosage adjustment is required for drugs that are mainly metabolized by CYP3A4 (e.g., midazolam), or for drugs that are metabolized by both CYP2D6 and CYP3A4 (e.g., tamoxifen, aripiprazole), when administered concomitantly with PRISTIQ [see section 5.3 Pharmacokinetic properties].</p><p>&nbsp;</p><p>Alcohol</p><p>A clinical study has shown that PRISTIQ does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking PRISTIQ.</p><p>&nbsp;</p><p><strong>Drug-Laboratory Test Interactions</strong></p><p>False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of desvenlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>&nbsp;</p><p><u>Risk </u><u>S</u><u>ummary</u></p><p>Based on data from published observational studies, exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see section 4.4 Special Warnings and Precautions for use and Clinical Considerations].</p><p>&nbsp;</p><p>There are no published studies on PRISTIQ in pregnant women; however published epidemiologic studies of pregnant women exposed to venlafaxine, the parent compound, have not reported a clear association with adverse developmental outcomes (see Data). There are risks associated with untreated depression in pregnancy and with exposure to SNRIs and SSRIs, including PRISTIQ, during pregnancy (see Clinical Considerations).</p><p>&nbsp;</p><p>In reproductive developmental studies in rats and rabbits treated with desvenlafaxine succinate, there was no evidence of teratogenicity at a plasma exposure (AUC) that is up to 19‑times (rats) and 0.5-times (rabbits) the exposure at an adult human dose of 100&nbsp;mg per day. However, fetotoxicity and pup deaths were observed in rats at 4.5-times the AUC exposure observed with an adult human dose of 100&nbsp;mg per day.</p><p>&nbsp;</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p><u>&nbsp;</u></p><p><u>Clinical </u><u>C</u><u>onsiderations</u></p><p>&nbsp;</p><p><em>Disease-associated maternal</em> <em>and/or embryo/fetal risk</em></p><p>A prospective longitudinal study of 201 women with a history of major depression who were euthymic at the beginning of pregnancy, showed that women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication.</p><p><em>&nbsp;</em></p><p><em>Maternal adverse reactions</em></p><p>Exposure to PRISTIQ in mid to late pregnancy may increase the risk for preeclampsia, and exposure to PRISTIQ in the month before delivery may be associated with an increased the risk of postpartum hemorrhage [see section 4.4 Special Warnings and Precautions for use].</p><p>&nbsp;</p><p>Observational data indicate an increased risk (less than 2-fold) of postpartum hemorrhage following SSRI/SNRI exposure within the month prior to birth.</p><p><em>&nbsp;</em></p><p><em>Fetal/Neonatal adverse reactions</em></p><p>Exposure to SNRIs or SSRIs in late pregnancy may lead to an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding. Monitor neonates who were exposed to PRISTIQ in the third trimester of pregnancy for drug discontinuation syndrome (see Data).</p><p><u>&nbsp;</u></p><p><u>Data</u></p><p><em>&nbsp;</em></p><p><em>Human </em><em>D</em><em>ata</em></p><p>Published epidemiological studies of pregnant women exposed to the parent compound venlafaxine have not reported a clear association with major birth defects or miscarriage. Methodological limitations of these observational studies include possible exposure and outcome misclassification, lack of adequate controls, adjustment for confounders, and confirmatory studies; therefore, these studies cannot establish or exclude any drug-associated risk during pregnancy.</p><p>&nbsp;</p><p>Retrospective cohort studies based on claims data have shown an association between venlafaxine use and preeclampsia, compared to depressed women who did not take an antidepressant during pregnancy. One study that assessed venlafaxine exposure in the second trimester or first half of the third trimester and preeclampsia showed an increased risk compared to unexposed depressed women [adjusted (adj) RR 1.57, 95% CI 1.29-1.91]. Preeclampsia was observed at venlafaxine doses equal to or greater than 75 mg/day and a duration of treatment &gt;30 days. Another study that assessed venlafaxine exposure in gestational weeks 10-20 and preeclampsia showed an increased risk at doses equal to or greater than 150&nbsp;mg/day. Available data are limited by possible outcome misclassification and possible confounding due to depression severity and other confounders.</p><p>&nbsp;</p><p>Retrospective cohort studies based on claims data have suggested an association between venlafaxine use near the time of delivery or through delivery and postpartum hemorrhage. One study showed an increased risk for postpartum hemorrhage when venlafaxine exposure occurred through delivery, compared to unexposed depressed women [adj RR 2.24 (95% CI 1.69-2.97)]. There was no increased risk in women who were exposed to venlafaxine earlier in pregnancy. Limitations of this study include possible confounding due to depression severity and other confounders. Another study showed an increased risk for postpartum hemorrhage when SNRI exposure occurred for at least 15 days in the last month of pregnancy or through delivery, compared to unexposed women (adj RR 1.64-1.76). The results of this study may be confounded by the effects of depression.</p><p>&nbsp;</p><p>Neonates exposed to SNRIs or SSRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome <em>[see </em>section 4.4 Special Warnings and Precautions for use<em>]</em>.</p><p>&nbsp;</p><p><em>Animal Data</em></p><p>When desvenlafaxine succinate was administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 300&nbsp;mg/kg/day and 75&nbsp;mg/kg/day, respectively, no teratogenic effects were observed. These doses were associated with a plasma exposure (AUC) 19 times (rats) and 0.5 times (rabbits) the AUC exposure at an adult human dose of 100&nbsp;mg per day. However, fetal weights were decreased, and skeletal ossification was delayed in rats in association with maternal toxicity at the highest dose, with an AUC exposure at the no-effect dose that is 4.5-times the AUC exposure at an adult human dose of 100&nbsp;mg per day.</p><p>&nbsp;</p><p>When desvenlafaxine succinate was administered orally to pregnant rats throughout gestation and lactation, there was a decrease in pup weights and an increase in pup deaths during the first four days of lactation at the highest dose of 300&nbsp;mg/kg/day. The cause of these deaths is not known. The AUC exposure at the no-effect dose for rat pup mortality was 4.5-times the AUC exposure at an adult human dose of 100&nbsp;mg per day. Post-weaning growth and reproductive performance of the progeny were not affected by maternal treatment with desvenlafaxine succinate at exposures 19 times the AUC exposure at an adult human dose of 100&nbsp;mg per day.</p><p>&nbsp;</p><p>Lactation</p><p><u>&nbsp;</u></p><p><u>Risk Summary</u></p><p>Available limited data from published literature show low levels of desvenlafaxine in human milk, and have not shown adverse reactions in breastfed infants (see Data). There are no data on the effects of desvenlafaxine on milk production.</p><p>The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for PRISTIQ and any potential adverse effects on the breastfed child from PRISTIQ or from the underlying maternal condition.</p><p><u>&nbsp;</u></p><p><u>Data</u></p><p>A lactation study was conducted in 10 breastfeeding women (at a mean of 4.3 months post‑partum) who were being treated with a 50-150 mg daily dose of desvenlafaxine for postpartum depression. Sampling was performed at steady state (up to 8 samples) over a 24&nbsp;hour dosing period, and included foremilk and hindmilk. The mean relative infant dose was calculated to be 6.8% (range of 5.5-8.1%). No adverse reactions were seen in the infants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interference with Cognitive and Motor Performance</u></p><p>Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that PRISTIQ therapy does not adversely affect their ability to engage in such activities.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are discussed in greater detail in other sections of the label.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity [see section 4.3 Contraindications]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serotonin Syndrome [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated Blood Pressure [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased Risk of Bleeding [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angle Closure Glaucoma [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Activation of Mania/Hypomania [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discontinuation Syndrome [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizure [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatremia [see 4.4 section Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial Lung Disease and Eosinophilic Pneumonia [see section 4.4 Special Warnings and Precautions for use]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual Dysfunction<em> </em>[see section 4.4 Special Warnings and Precautions for use]</p><p>&nbsp;</p><p>Clinical Studies Experience</p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.</p><p><u>&nbsp;</u></p><p><u>Patient exposure</u></p><p>PRISTIQ was evaluated for safety in 8,394 patients diagnosed with major depressive disorder who participated in multiple-dose pre-marketing studies, representing 2,784 patient-years of exposure. Of the total 8,394 patients exposed to at least one dose of PRISTIQ; 2,116 were exposed to PRISTIQ for 6 months, representing 1,658 patient-years of exposure, and 421 were exposed for one year, representing 416 patient-years of exposure.</p><p>&nbsp;</p><p><u>Adverse reactions reported as reasons for discontinuation of treatment</u></p><p>In the pre-marketing pooled 8-week placebo-controlled studies in patients with MDD, 1,834&nbsp;patients were exposed to PRISTIQ (50 to 400 mg). Of the 1,834 patients, 12% discontinued treatment due to an adverse reaction, compared with 3% of the 1,116 placebo‑treated patients. At the recommended dose of 50 mg, the discontinuation rate due to an adverse reaction for PRISTIQ (4.1%) was similar to the rate for placebo (3.8%). For the 100&nbsp;mg dose of PRISTIQ the discontinuation rate due to an adverse reaction was 8.7%.</p><p>&nbsp;</p><p>The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8&nbsp;weeks, were: nausea (4%); dizziness, headache and vomiting (2% each). In a longer-term study, up to 9 months, the most common was vomiting (2%).</p><p><u>&nbsp;</u></p><p><u>Common adverse reactions in placebo-controlled MDD studies</u></p><p>The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence &ge;&nbsp;5% and at least twice the rate of placebo in the 50 or 100&nbsp;mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.</p><p>&nbsp;</p><p>Table 3 shows the incidence of common adverse reactions that occurred in &ge;&nbsp;2% of PRISTIQ treated MDD patients and twice the rate of placebo at any dose in the pre-marketing pooled 8‑week, placebo‑controlled, fixed dose clinical studies.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="6"><p>Table 3: Common Adverse Reactions (&ge; 2% in any Fixed-Dose Group and Twice the Rate of Placebo) in <strong>Pre-marketing Pooled MDD 8‑Week Placebo-Controlled Studies</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="5"><p>Percentage of Patients Reporting Reaction</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="4"><p>PRISTIQ</p></td></tr><tr><td><p>System Organ Class Preferred Term</p></td><td><p>Placebo</p><p>(n=636)</p></td><td><p>50 mg</p><p>(n=317)</p></td><td><p>100 mg</p><p>(n=424)</p></td><td><p>200 mg</p><p>(n=307)</p></td><td><p>400 mg</p><p>(n=317)</p></td></tr></thead><tbody><tr><td colspan="6" style="vertical-align:top"><p>Cardiac disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Blood pressure increased</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Gastrointestinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Nausea</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>41</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Dry mouth</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Constipation</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Vomiting</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>General disorders and administration site conditions</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Fatigue</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Chills</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Feeling jittery</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Decreased appetite</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Nervous system disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Dizziness</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Somnolence</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Tremor</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Disturbance in attention</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Psychiatric disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Insomnia</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Anxiety</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Nervousness</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Abnormal dreams</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Renal and urinary disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Urinary hesitation</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Yawning</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Hyperhidrosis</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td colspan="6"><p>Special Senses</p></td></tr><tr><td><p>&nbsp;&nbsp;Vision blurred</p></td><td><p>1</p></td><td><p>3</p></td><td><p>4</p></td><td><p>4</p></td><td><p>4</p></td></tr><tr><td><p>&nbsp;&nbsp;Mydriasis</p></td><td><p>&lt;1</p></td><td><p>2</p></td><td><p>2</p></td><td><p>6</p></td><td><p>6</p></td></tr><tr><td><p>&nbsp;&nbsp;Vertigo</p></td><td><p>1</p></td><td><p>2</p></td><td><p>1</p></td><td><p>5</p></td><td><p>3</p></td></tr><tr><td><p>&nbsp;&nbsp;Tinnitus</p></td><td><p>1</p></td><td><p>2</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td></tr><tr><td><p>&nbsp;&nbsp;Dysgeusia</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Vascular disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;Hot flush</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Sexual function adverse reactions</u></p><p>Table 4 shows the incidence of sexual function adverse reactions that occurred in &ge;&nbsp;2% of PRISTIQ treated MDD patients in any fixed-dose group (pre-marketing pooled 8‑week, placebo-controlled, fixed -dose, clinical studies). [see section 4.4 Special Warnings and Precautions for use].</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="6"><p>Table 4: Sexual Function Adverse Reactions (&ge; 2% in Men or Women in any PRISTIQ Group) During the On-Therapy Period</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="4"><p>PRISTIQ</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p>Placebo</p><p>(n=239)</p></td><td style="vertical-align:bottom"><p>50 mg</p><p>(n=108)</p></td><td style="vertical-align:bottom"><p>100 mg</p><p>(n=157)</p></td><td style="vertical-align:bottom"><p>200 mg</p><p>(n=131)</p></td><td style="vertical-align:bottom"><p>400 mg</p><p>(n=154)</p></td></tr></thead><tbody><tr><td colspan="6"><p><strong>&nbsp; Men only</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Anorgasmia</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Libido decreased</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Orgasm abnormal</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Ejaculation delayed</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Erectile dysfunction</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Ejaculation disorder</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Ejaculation failure</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Sexual dysfunction</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="4"><p>PRISTIQ</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Placebo</p><p>(n=397)</p></td><td style="vertical-align:bottom"><p>50 mg</p><p>(n=209)</p></td><td style="vertical-align:bottom"><p>100 mg</p><p>(n=267)</p></td><td style="vertical-align:bottom"><p>200 mg</p><p>(n=176)</p></td><td style="vertical-align:bottom"><p>400 mg</p><p>(n=163)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>&nbsp; &nbsp;Women only</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Anorgasmia</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Other adverse reactions observed in premarketing and postmarketing clinical studies</u></p><p>Other infrequent adverse reactions, not described elsewhere in the label, occurring at an incidence of &lt;&nbsp;2% in MDD patients treated with PRISTIQ were:</p><p>&nbsp;</p><p><strong>Cardiac disorders</strong> &ndash; Tachycardia.</p><p><strong>General disorders and administration site conditions</strong> &ndash; Asthenia.</p><p><strong>Investigations &ndash;</strong> Weight increased, liver function test abnormal, blood prolactin increased.</p><p><strong>Musculoskeletal and connective tissue disorders &ndash;</strong> Musculoskeletal stiffness.</p><p><strong>Nervous system disorders &ndash;</strong>Syncope, convulsion, dystonia.</p><p><strong>Psychiatric disorders &ndash;</strong> Depersonalization, bruxism.</p><p><em>Renal and urinary disorders</em> &ndash; Urinary retention.</p><p><em>Skin and subcutaneous tissue disorders</em> &ndash; Rash, alopecia, photosensitivity reaction, angioedema.</p><p>&nbsp;</p><p>In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during PRISTIQ treatment as compared to placebo.</p><p><strong><em>Reproductive system and breast disorder</em></strong> &ndash; postpartum haemorrhage[1]; frequency not known.</p><p>[1] This event has been reported for the therapeutic class of SSRIs/SNRIs</p><p>&nbsp;</p><p><u>Laboratory, ECG and vital sign changes observed in MDD clinical studies</u></p><p>The following changes were observed in pre-marketing placebo-controlled, short-term MDD studies with PRISTIQ.</p><p>&nbsp;</p><p>Lipids</p><p>Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potentially clinically significant.</p><p>&nbsp;</p><p>The percentage of patients who exceeded a predetermined threshold value is shown in Table&nbsp;5.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="9"><p>Table 5: Incidence (%) of Patients with Lipid Abnormalities of Potential Clinical Significance*</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="7" style="vertical-align:bottom"><p>PRISTIQ</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Placebo</p></td><td style="vertical-align:bottom"><p>50 mg</p></td><td colspan="2" style="vertical-align:bottom"><p>100 mg</p></td><td colspan="3" style="vertical-align:bottom"><p>200 mg</p></td><td style="vertical-align:bottom"><p>400 mg</p></td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p>Total Cholesterol<br />*(Increase of &ge; 50 mg/dl and an absolute value of &ge;&nbsp;261&nbsp;mg/dl)</p></td><td style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:bottom"><p>LDL Cholesterol<br />*(Increase &ge; 50 mg/dl and an absolute value of &ge;&nbsp;190&nbsp;mg/dl)</p></td><td style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:bottom"><p>Triglycerides, fasting<br />*(Fasting: &ge; 327 mg/dl)</p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>6</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Proteinuria</p><p>Proteinuria, greater than or equal to trace, was observed in the pre-marketing fixed-dose controlled studies (see Table 6). This proteinuria was not associated with increases in BUN or creatinine and was generally transient.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="6"><p>Table 6: Incidence (%) of Patients with Proteinuria in the Fixed-dose Clinical Studies</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:bottom"><p>PRISTIQ</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Placebo</p></td><td style="vertical-align:bottom"><p>50 mg</p></td><td style="vertical-align:bottom"><p>100 mg</p></td><td style="vertical-align:bottom"><p>200 mg</p></td><td style="vertical-align:bottom"><p>400 mg</p></td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p>Proteinuria</p></td><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>6</p></td><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:bottom"><p>7</p></td></tr></tbody></table><p>&nbsp;</p><p>Vital sign changes</p><p>Table 7 summarizes the changes that were observed in placebo-controlled, short-term, pre‑marketing studies with PRISTIQ in patients with MDD (doses 50 to 400&nbsp;mg).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="6"><p>Table 7: Mean Changes in Vital Signs at Final on Therapy for All Short-term, Fixed-dose Controlled Studies</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:bottom"><p>PRISTIQ</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Placebo</p></td><td style="vertical-align:bottom"><p>50 mg</p></td><td style="vertical-align:bottom"><p>100 mg</p></td><td style="vertical-align:bottom"><p>200 mg</p></td><td style="vertical-align:bottom"><p>400 mg</p></td></tr></thead><tbody><tr><td colspan="6" style="vertical-align:bottom"><p>Blood pressure</p></td></tr><tr><td style="vertical-align:bottom"><p>Supine systolic bp (mm Hg)</p></td><td style="vertical-align:top"><p>-1.4</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>2.0</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:bottom"><p>Supine diastolic bp (mm Hg)</p></td><td style="vertical-align:top"><p>-0.6</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td colspan="6" style="vertical-align:bottom"><p>Pulse rate</p></td></tr><tr><td style="vertical-align:bottom"><p>Supine pulse (bpm)</p></td><td style="vertical-align:top"><p>-0.3</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>4.1</p></td></tr><tr><td style="vertical-align:bottom"><p>Weight (kg)</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-0.6</p></td><td style="vertical-align:top"><p>-0.9</p></td><td style="vertical-align:top"><p>-1.1</p></td></tr></tbody></table><p>&nbsp;</p><p>Treatment with PRISTIQ at all doses from 50&nbsp;mg per day to 400&nbsp;mg per day in controlled studies was associated with sustained hypertension, defined as treatment-emergent supine diastolic blood pressure (SDBP) &ge;90&nbsp;mm Hg and &ge;10&nbsp;mm Hg above baseline for 3 consecutive on-therapy visits (see Table 8). Analyses of patients in PRISTIQ pre-marketing short‑term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension. This was seen at all doses with a suggestion of a higher rate at 400&nbsp;mg per day.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:648px"><thead><tr><td colspan="2"><p>Table 8: Proportion of Patients with Sustained Elevation of Supine Diastolic Blood Pressure</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Treatment Group</p></td><td colspan="2" style="vertical-align:bottom"><p>Proportion of Patients with Sustained Hypertension</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>0.5%</p></td></tr><tr><td style="vertical-align:top"><p>PRISTIQ 50 mg per day</p></td><td colspan="2" style="vertical-align:top"><p>1.3%</p></td></tr><tr><td style="vertical-align:top"><p>PRISTIQ 100 mg per day</p></td><td colspan="2" style="vertical-align:top"><p>0.7%</p></td></tr><tr><td style="vertical-align:top"><p>PRISTIQ 200 mg per day</p></td><td colspan="2" style="vertical-align:top"><p>1.1%</p></td></tr><tr><td style="vertical-align:top"><p>PRISTIQ 400 mg per day</p></td><td colspan="2" style="vertical-align:top"><p>2.3%</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Orthostatic hypotension</p><p>In the pre-marketing short-term, placebo-controlled clinical studies with doses of 50 to 400&nbsp;mg, systolic orthostatic hypotension (decrease &ge;30&nbsp;mm Hg from supine to standing position) occurred more frequently in patients &ge;65&nbsp;years of age receiving PRISTIQ (8%, 7/87) versus placebo (2.5%,&nbsp;1/40), compared to patients &lt;65&nbsp;years of age receiving PRISTIQ (0.9%, 18/1,937) versus placebo (0.7%, 8/1,218).</p><p>&nbsp;</p><p>Postmarketing Experience</p><p>&nbsp;</p><p>The following adverse reaction has been identified during post-approval use of PRISTIQ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:</p><p>&nbsp;</p><p><strong>Skin and subcutaneous tissue disorders</strong> &ndash; Stevens-Johnson syndrome</p><p><strong><em>Gastrointestinal disorders</em></strong> &ndash; Pancreatitis acute</p><p><strong><em>Cardiovascular system</em></strong> &ndash; Takotsubo cardiomyopathy</p><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong> - Anosmia, hyposmia</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local requirements.</p><p><u>&nbsp;</u></p><p>To report any side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Controlled Substance</p><p>&nbsp;</p><p>PRISTIQ is not a controlled substance.</p><p>&nbsp;</p><p>Human Experience with Overdosage</p><p>&nbsp;</p><p>There is limited clinical trial experience with desvenlafaxine succinate overdosage in humans. However, desvenlafaxine (PRISTIQ) is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of PRISTIQ) is presented below; the identical information can be found in the Overdosage section of the venlafaxine package insert.</p><p>&nbsp;</p><p>In postmarketing experience, overdose with venlafaxine (the parent drug of PRISTIQ) has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdosage include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (e.g.,&nbsp;prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported.</p><p>&nbsp;</p><p>Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI‑treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear.</p><p>&nbsp;</p><p>Management of Overdosage</p><p>&nbsp;</p><p>No specific antidotes for PRISTIQ are known. In managing over dosage, consider the possibility of multiple drug involvement. In case of overdose, call National Drug and Poison Information Center (NDPIC) for latest recommendations.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of Action</p><p>&nbsp;</p><p>The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective SNRI.</p><p>Desvenlafaxine lacked significant affinity for numerous receptors, including muscarinic‑cholinergic, H<sub>1</sub>-histaminergic, or &alpha;<sub>1</sub>-adrenergic receptors in vitro. Desvenlafaxine also lacked monoamine oxidase (MAO) inhibitory activity.</p><p><u>&nbsp;</u></p><p><u>ECG changes</u></p><p>Electrocardiograms were obtained from 1,492 desvenlafaxine treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8&nbsp;weeks. No clinically relevant differences were observed between desvenlafaxine treated and placebo‑treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval.</p><p>&nbsp;</p><p>CLINICAL STUDIES</p><p>&nbsp;</p><p><u>Major Depressive Disorder</u></p><p>The efficacy of PRISTIQ as a treatment for depression was established in four 8‑week, randomized, double-blind, placebo-controlled, fixed-dose studies (at doses of 50&nbsp;mg per day to 400&nbsp;mg per day) in adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder. In the first study, patients received 100&nbsp;mg (n&nbsp;=&nbsp;114), 200&nbsp;mg (n&nbsp;=&nbsp;116), or 400&nbsp;mg (n&nbsp;=&nbsp;113) of PRISTIQ once daily, or placebo (n&nbsp;=&nbsp;118). In a second study, patients received either 200&nbsp;mg (n&nbsp;=&nbsp;121) or 400&nbsp;mg (n&nbsp;=&nbsp;124) of PRISTIQ once daily, or placebo (n&nbsp;=&nbsp;124). In two additional studies, patients received 50&nbsp;mg (n&nbsp;=&nbsp;150 and n&nbsp;=&nbsp;164) or 100&nbsp;mg (n&nbsp;=&nbsp;147 and n&nbsp;=&nbsp;158) of PRISTIQ once daily, or placebo (n&nbsp;=&nbsp;150 and n&nbsp;=&nbsp;161).</p><p>&nbsp;</p><p>PRISTIQ showed superiority over placebo as measured by improvement in the 17‑item Hamilton Rating Scale for Depression (HAM-D<sub>17</sub>) total score in four studies and overall improvement, as measured by the Clinical Global Impressions Scale - Improvement (CGI‑I), in three of the four studies. In studies directly comparing 50&nbsp;mg per day and 100&nbsp;mg per day there was no suggestion of a greater effect with the higher dose and adverse reactions and discontinuations were more frequent at higher doses [see section 4.2 Posology and method of administration].</p><p>&nbsp;</p><p><strong>Table 9: Primary Efficacy (HAM-D<sub>17</sub>) Results for Short-term Studies</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:644px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>PRISTIQ</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Study No.</strong></p></td><td style="vertical-align:top"><p><strong>Primary Endpoint: HAM-D<sub>17</sub></strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>50 mg/day</strong></p></td><td style="vertical-align:top"><p><strong>100 mg/day</strong></p></td><td style="vertical-align:top"><p><strong>200 mg/day</strong></p></td><td style="vertical-align:top"><p><strong>400 mg/day</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>1<br /><br /><br />&nbsp;</p></td><td style="vertical-align:top"><p>Baseline Score (SD<sup>a</sup>)</p></td><td style="vertical-align:top"><p>23.1 (2.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>23.2 (2.5)</p></td><td style="vertical-align:top"><p>22.9 (2.4)</p></td><td style="vertical-align:top"><p>23.0 (2.2)</p></td></tr><tr><td><p>Difference from Placebo (95% CI<sup> c</sup>)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>-2.9<sup>b</sup><br />&nbsp;(-5.1, -0.8)</p></td><td><p>-2.0<br />&nbsp;</p></td><td><p>-3.1<sup>b</sup><br />(-5.2, -0.9)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>2<br /><br /><br />&nbsp;</p></td><td><p>Baseline Score (SD<sup>a</sup>)</p></td><td style="vertical-align:top"><p>25.3 (3.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>24.8 (2.9)</p></td><td style="vertical-align:top"><p>25.2 (3.2)</p></td></tr><tr><td><p>Difference from Placebo (95% CI<sup> c</sup>)<sup> </sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>-3.3<sup>b</sup><br />&nbsp;(-5.3, -1.2)</p></td><td><p>-2.8<sup>b</sup><br />&nbsp;(-4.8, -0.7)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>3<br /><br /><br />&nbsp;</p></td><td><p>Baseline Score (SD<sup>a</sup>)</p></td><td><p>23.0 (2.6)</p></td><td><p>23.4 (2.6)</p></td><td><p>23.4 (2.6)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Difference from Placebo (95% CI<sup> c</sup>)<sup> </sup></p></td><td><p>&nbsp;</p></td><td><p>-1.9<sup>b</sup><br />&nbsp;(-3.5, -0.3)</p></td><td><p>-1.5<br />&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>4<br /><br /><br />&nbsp;</p></td><td><p>Baseline Score (SD<sup>a</sup>)</p></td><td><p>24.3 (2.6)</p></td><td><p>24.3 (2.4)</p></td><td><p>24.4 (2.7)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Difference from Placebo (95% CI<sup> c</sup>)<sup> </sup></p></td><td><p>&nbsp;</p></td><td><p>-2.5<sup>b</sup><br />(-4.1, -0.9)</p></td><td><p>-3.0<sup>b</sup><br />&nbsp;(-4.7, -1.4)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup> Standard deviation.</p><p><sup>b</sup> Adjusted p-value &lt; 0.05;<br /><sup>c </sup>Difference between least squares means at final evaluation, calculated as drug response minus placebo response; unadjusted 95% confidence intervals</p></td></tr></tbody></table><p>&nbsp;</p><p>Analyses of the relationships between treatment outcome and age and treatment outcome and gender did not suggest any differential responsiveness on the basis of these patient characteristics. There was insufficient information to determine the effect of race on outcome in these studies.</p><p>&nbsp;</p><p>In a longer-term trial (Study 5), adult outpatients meeting DSM-IV criteria for major depressive disorder, who responded to 8 weeks of open-label acute treatment with 50&nbsp;mg per day desvenlafaxine and subsequently remained stable for 12 weeks on desvenlafaxine, were assigned randomly in a double-blind manner to remain on active treatment or switch to placebo for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a HAM-D<sub>17</sub> total score of &le; 11 and CGI-I &le; 2 at the day 56 evaluation; stability was defined as HAM-D<sub>17</sub> total score of &le; 11 and CGI-I &le; 2 at week 20 and not having a HAM-D<sub>17</sub> total score of &sup3; 16 or a CGI-I score &sup3; 4 at any office visit. Relapse during the double-blind phase was defined as follows: (1) a HAM-D<sub>17</sub> total score of &sup3; 16 at any office visit, (2) discontinuation for unsatisfactory efficacy response, (3) hospitalized for depression, (4) suicide attempt, or (5) suicide. Patients receiving continued desvenlafaxine treatment experienced statistically significantly longer time to relapse compared with placebo. At 26 weeks, the Kaplan-Meier estimated proportion of relapse was 14% with desvenlafaxine treatment versus 30% with placebo.</p><p><strong>&nbsp;</strong></p><p><strong>Figure 1. Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5)</strong></p><p><strong><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Image_x0020_22" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:438pt;height:310.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="584" height="414" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></strong></p><p>&nbsp;</p><p>In another longer-term trial (Study 6), adult outpatients meeting DSM-IV criteria for major depressive disorder and who responded to 12 weeks of acute treatment with desvenlafaxine were assigned randomly to the same dose (200 or 400&nbsp;mg per day) they had received during acute treatment or to placebo for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a HAM-D<sub>17</sub> total score of &le; 11 at the day 84 evaluation. Relapse during the double-blind phase was defined as follows: (1) a HAM-D<sub>17</sub> total score of <u>&gt;</u>&nbsp;16 at any office visit, (2) a CGI-I score of &ge; 6 (versus day 84) at any office visit, or (3) discontinuation from the trial due to unsatisfactory response. Patients receiving continued desvenlafaxine treatment experienced statistically significantly longer time to relapse over the subsequent 26 weeks compared with those receiving placebo. At 26 weeks, the Kaplan-Meier estimated proportion of relapse was 29% with desvenlafaxine treatment versus 49% with placebo.</p><p><strong>Figure 2. Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 6)</strong></p><p><!--[if gte vml 1]><v:shape id="Image_x0020_23"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:446pt;height:317pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="595" height="423" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;</p><p>In a postmarketing study, the efficacy of PRISTIQ at a dose lower than 50&nbsp;mg per day was evaluated in an 8-week, multicenter, randomized, double-blind, placebo-controlled, fixed‑dose study in adult outpatients with Major Depressive Disorder. The treatment arms were 25&nbsp;mg (n=232), 50 mg (n=236), and placebo (n=231). The 50&nbsp;mg dose was superior to placebo, as measured by the mean change from baseline on the HAMD-17. The 25&nbsp;mg dose was not superior to placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The single-dose pharmacokinetics of desvenlafaxine are linear and dose-proportional in a dose range of 50 to 600&nbsp;mg (1 to 12 times the recommended approved dosage) per day. With once‑daily dosing, steady-state plasma concentrations are achieved within approximately 4 to 5&nbsp;days. At steady-state, multiple-dose accumulation of desvenlafaxine is linear and predictable from the single-dose pharmacokinetic profile.</p><p><u>&nbsp;</u></p><p><u>Absorption</u><em> </em></p><p>The absolute oral bioavailability of PRISTIQ after oral administration is about 80%.</p><p><em>&nbsp;</em></p><p><em>Effect of Food</em></p><p>Ingestion of a high-fat meal (800 to 1000&nbsp;calories) increased desvenlafaxine C<sub>max</sub> about 16% and had no effect on AUC.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>Steady‑state volume of distribution of desvenlafaxine is 3.4&nbsp;L/kg. Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><em>&nbsp;</em></p><p><em>Metabolism</em></p><p>Desvenlafaxine is primarily metabolized by conjugation (mediated by UGT isoforms) and, to a minor extent, through oxidative metabolism. CYP3A4 mediates the oxidative metabolism (N‑demethylation) of desvenlafaxine. The CYP2D6 metabolic pathway&nbsp;is not involved. The pharmacokinetics of desvenlafaxine was similar in subjects with CYP2D6 poor and extensive metabolizer phenotype.</p><p><em>&nbsp;</em></p><p><em>Excretion</em></p><p>Approximately 45% of desvenlafaxine is excreted unchanged in urine at 72 hours after oral administration. Approximately 19% of the administered dose is excreted as the glucuronide metabolite and &lt;5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine.</p><p><u>&nbsp;</u></p><p><u>Speci</u><u>fic</u><u> </u><u>P</u><u>opulations</u></p><p>No clinically significant differences in the exposures of desvenlafaxine were observed based on ethnicity (White, Black, Hispanic).</p><p>&nbsp;</p><p>The effect of intrinsic patient factors on the pharmacokinetics of desvenlafaxine is presented in Figure 3.</p><p>&nbsp;</p><p>Figure 3 Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) on Desvenlafaxine Pharmacokinetics</p><p>&nbsp;</p><p><strong><u><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_13" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:408pt;height:427pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title="Figure38414088999797409558"/>
</v:shape><![endif]--><img width="544" height="569" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></u></strong></p><p><u>&nbsp;</u></p><p><u>Drug Interaction Studies</u></p><p>&nbsp;</p><p><em>Clinical Studies</em></p><p><em>&nbsp;</em></p><p><em><u>Other Drugs on PRISTIQ</u></em></p><p>The effect of ketoconazole on the exposures of desvenlafaxine is summarized in Figure 4.</p><p>&nbsp;</p><p><strong>Figure 4. Effect of Other Drugs on Desvenlafaxine Pharmacokinetics</strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_11" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:434.5pt;
 height:187pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
  o:title="Figure18970595118670006744"/>
</v:shape><![endif]--><img width="579" height="249" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></p><p><em><u>&nbsp;</u></em></p><p><em><u>PRISTIQ</u></em><u> <em>on Other Drugs</em></u></p><p>The effects of PRISTIQ on the exposures of other drugs are summarized in Figure 5.</p><p>&nbsp;</p><p><strong>Figure 5. Effects of PRISTIQ on Pharmacokinetics of Other Drugs</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_12" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:456pt;
 height:413.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
  o:title="Figure23462652637904925433"/>
</v:shape><![endif]--><img width="608" height="551" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.jpg" /></p><p>&nbsp;</p><p><em>In Vitro Studies</em></p><p>Based on <em>in vitro</em> data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of desvenlafaxine.</p><p>&nbsp;</p><p>Desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, 2C19 CYP2D6, or CYP3A4 isozymes. Desvenlafaxine does not induce CYP3A4 either.</p><p>&nbsp;</p><p>Desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein (P-gp) transporter.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p><u>&nbsp;</u></p><p><u>Carcinogenesis</u></p><p>Desvenlafaxine succinate administered by oral gavage to mice and rats for 2 years did not increase the incidence of tumors in either study.</p><p>&nbsp;</p><p>Mice received desvenlafaxine succinate at dosages up to 500/300&nbsp;mg/kg/day (dosage lowered after 45 weeks of dosing). The AUC exposure at 300&nbsp;mg/kg/day dose is estimated at 10&nbsp;times the AUC exposure at an adult human dose of 100&nbsp;mg per day.</p><p>&nbsp;</p><p>Rats received desvenlafaxine succinate at dosages up to 300&nbsp;mg/kg/day (males) or 500&nbsp;mg/kg/day (females). The AUC exposure at the highest dose is estimated at 11 (males) or 26 (females) times the AUC exposure at an adult human dose of 100&nbsp;mg per day.</p><p><u>&nbsp;</u></p><p><u>Mutagenesis</u></p><p>Desvenlafaxine was not mutagenic in the in vitro bacterial mutation assay (Ames test) and was not clastogenic in an in vitro chromosome aberration assay in cultured CHO cells, an in vivo mouse micronucleus assay, or an in vivo chromosome aberration assay in rats. Additionally, desvenlafaxine was not genotoxic in the in vitro CHO mammalian cell forward mutation assay and was negative in the in vitro BALB/c-3T3 mouse embryo cell transformation assay.</p><p><u>&nbsp;</u></p><p><u>Impairment of Fertility</u></p><p>When desvenlafaxine succinate was administered orally to male and female rats, fertility was reduced at the high dose of 300&nbsp;mg/kg/day, which is 10 (males) and 19 (females) times the AUC exposure at an adult human dose of 100 mg per day. There was no effect on fertility at 100&nbsp;mg/kg/day, which is 3 (males) or 5 (females) times the AUC exposure at an adult human dose of 100 mg per day. These studies did not address reversibility of the effect on fertility. The relevance of these findings to humans is not known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inactive ingredients for the 50 mg core tablet are hypromellose, microcrystalline cellulose, talc, and magnesium stearate. Depending on the region, film coating can be either: Opaglos 2, which consists of sodium carboxymethylcellulose, maltodextrin, dextrose, titanium dioxide, stearic acid and red iron oxide, or Opadry II, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxides.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Pristiqe after the expiry date which is stated on the Bottle after EXP: The expiry date refers to the last day of that month.

Shelf life 36 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pristiq 50&nbsp;mg extended-release tablets are available as a bottle of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p><u>&nbsp;</u></p><p><u>Residual inert matrix tablet</u></p><p>Patients receiving desvenlafaxine succinate may notice an inert matrix tablet passing in the stool or via colostomy. Patients should be informed that the active medication has already been absorbed by the time the patient sees the inert matrix tablet.</p><p><strong>&nbsp;</strong></p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Inc. - United states.

MANUFACTURED BY
Pfizer Ireland Pharmaceuticals, Newbridge, Ireland

PACKED & RELEASED BY
Pfizer Pharmaceutical LLC, Vega Baja, PR - United States.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>